Transdermal absorption drug for skin prepared from hydrocortisone butyrate containing adjuvant and water containing adjuvant

A technology of hydrocortisone butyrate and pharmaceutical excipients, which is applied in the direction of medical preparations containing active ingredients, skin diseases, drug combinations, etc., and can solve the problem of particle instability and the inability to guarantee particle suspension Ostwald Ripening and other issues to achieve the effect of reducing waste and ensuring the stability of the suspension

Active Publication Date: 2012-07-11
TIANJIN JINYAO GRP
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] How to solve the problem of particle instability in microparticle suspensions has always been one of the problems to be solved in pharmacy, but no matter whether by adding excipients or improving the particle structure, there is no guarantee that microparticle suspensions will not appear Osmos during storage. Twald ripening, especially with multiple uses of dermal suspensions, is more likely to occur

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transdermal absorption drug for skin prepared from hydrocortisone butyrate containing adjuvant and water containing adjuvant
  • Transdermal absorption drug for skin prepared from hydrocortisone butyrate containing adjuvant and water containing adjuvant
  • Transdermal absorption drug for skin prepared from hydrocortisone butyrate containing adjuvant and water containing adjuvant

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0039] 1. Preparation of drug particles for transdermal absorption

[0040] The capsules packed with the drug microparticles obtained in Examples 1 to 10 are plant capsules, and the capsules are sealed and packaged with aluminum foil blisters after packing. The water containing auxiliary materials obtained in Examples 11 and 12 is sealed and packed in ampoules.

Embodiment 1

[0042] Dissolve 0.2g of hydrocortisone butyrate in ethanol, filter, sterilize, spray-dry the filtrate, micronize the particle size to 3 μm, mix it with 1.5 g of crystalline lactose with a particle size of 30 μm, and pass it through a 200-mesh sieve 3 After mixing evenly for the first time, it is divided into No. 2 capsules, and each capsule contains 2 mg of hydrocortisone butyrate. Electron microscope observation shows that the drug particles are spherical.

[0043] The process conditions are: the inlet temperature is 100°C, the outlet temperature is 70°C, the air flow rate is 90%, the inner diameter of the nozzle outlet is 0.1cm, the air flow rate of the nozzle is 800ml / min, and the injection speed is 50mL / h

Embodiment 2

[0045] Dissolve 1 g of hydrocortisone butyrate in ethanol, filter, spray-dry the filtrate, micronize the particle size to 3 μm, mix it with 15 g of crystalline lactose with a particle size of 30 μm, mix it with a 200 mesh sieve for 3 times, and then sterilize Bacteria, divided into No. 2 capsules, each capsule contains 1mg of hydrocortisone butyrate. Electron microscope observation shows that the particles are spherical.

[0046] The process conditions are as follows: inlet temperature is 105°C, outlet temperature is 70°C, air flow rate is 90%, nozzle outlet inner diameter is 0.1cm, nozzle air flow rate is 800ml / min, and sample injection speed is 50mL / h.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a transdermal absorption drug for skin prepared from hydrocortisone butyrate containing adjuvant and water containing adjuvant. The transdermal absorption drug is prepared from single-packaged hydrocortisone butyrate and single-packaged water, wherein the hydrocortisone butyrate contains one or several kinds of solid pharmaceutical adjuvant and is difficult to dissolve in water, and the D90 grain size of the hydrocortisone butyrate is 0.1-10mum; and the water contains one or several kinds of water-soluble pharmaceutical adjuvant.

Description

Technical field: [0001] The invention relates to a medicine for skin, which is composed of one or several auxiliary materials for skin medicine and hydrocortisone butyrate and water containing the auxiliary materials in separate packaging. Background technique: [0002] Skin inflammations such as eczema, allergic dermatitis, atopic dermatitis, and urticaria are caused by allergic reactions caused by certain allergens. [0003] In the skin drug delivery system, the skin is the main barrier for drugs to enter the body. Studies have found that only a few drugs have excellent skin permeability, and most drugs are not easy to pass through the effective and selective barrier of human skin. Drugs with higher solubility cross the epidermis more easily. In the treatment of skin diseases, the most common type of preparation is transdermal drug delivery, transdermal drug delivery system or transdermal drug delivery system (transdermal thrapeutic systems, transdermal drug delivery syst...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/573A61K9/10A61P17/00A61P17/08A61P37/08
Inventor 孙亮陈松赵琳
Owner TIANJIN JINYAO GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products